Deficient expression of p21Cip1/Waf1 is observed in gastric cancer and non-small cell lung cancer, while overexpression of p21Cip1/Waf1 in prostate cancer is associated with worse clinical outcome [37]. This evidence concerns the gene CDKN1A and prostate cancer.